Among the eight LCC patients under the 2015 WHO criteria, four LCC patients presented TP53 (50%) mutations, and two patients presented concurrent TP53 and KRAS mutations. This evidence concerns the gene TP53 and leukoencephalopathy with calcifications and cysts.